Hypothesis

Acarbose extends lifespan partly by reshaping the gut microbiome toward increased butyrate‑producing taxa. The resulting rise in colonic butyrate crosses the blood‑brain barrier via monocarboxylate transporters and acts as an endogenous histone deacetylase (HDAC) inhibitor in hippocampal neurons. This epigenetic shift reduces HDAC‑mediated repression of plasticity‑related genes (e.g., Bdnf, Arc) while simultaneously lowering the expression of synaptic stabilization proteins such as PSD‑95. The net effect is a reduction in excessive synaptic consolidation—what we term "over‑consolidation"—thereby re‑introducing a tolerable level of uncertainty that restores cognitive flexibility in aged animals.

Novel Mechanistic Reasoning

1. Microbiome‑butyrate axis – Acarbose‑driven expansion of Bifidobacteriaceae and Bacteroidaceae elevates fecal butyrate (see microbiome SCFA shifts and diet‑dependent microbiota changes).
2. Butyrate as an HDAC inhibitor – Butyrate enters neurons and inhibits class I HDACs, increasing histone acetylation at promoters of neuroplasticity genes. This mirrors the BDNF‑boosting effect of caloric restriction (BDNF & IGF‑1 link).
3. Epigenetic re‑tuning of consolidation – Elevated acetylation reduces transcriptional repression of Bdnf and Arc, boosting BDNF‑TrkB signaling. Activated TrkB pathways trigger downstream phosphatases (e.g., STEP) that destabilize PSD‑95‑anchored receptor complexes, weakening overly stable synapses without causing global synapse loss.
4. Behavioral outcome – A hippocampal network with lower PSD‑95‑mediated rigidity shows improved reversal learning and set‑shifting, directly addressing the over‑consolidation model of cognitive aging.

Testable Predictions

• Aged HET3 mice receiving acarbose will show higher fecal butyrate levels than controls.
• Hippocampal tissue from acarbose‑treated mice will exhibit decreased HDAC activity and increased histone H3 acetylation at Bdnf and Arc promoters.
• PSD‑95 protein abundance in the synaptosomal fraction will be reduced, while total synapse number remains unchanged.
• Acarbose‑treated aged mice will commit fewer errors in a reversed Morris water maze or a tactile discrimination set‑shifting task, indicating rescued cognitive flexibility.
• Antibiotic ablation of gut microbiota or pharmacological blockade of the butyrate receptor GPR109A will abolish the HDAC inhibition, PSD‑95 reduction, and behavioral improvements despite acarbose administration.

Experimental Design (brief)

Subjects: 20‑month‑old HET3 mice (both sexes), n=12 per group. Groups: (1) Control chow, (2) Control + broad‑spectrum antibiotics, (3) Acarbose (0.2% w/w), (4) Acarbose + antibiotics, (5) Acarbose + GPR109A antagonist. Duration: 12 weeks. Readouts: fecal butyrate (GC‑MS), hippocampal HDAC activity (fluorometric assay), histone acetylation (Western blot for H3K9ac), PSD‑95 and synaptophysin (Western blot), reversal learning performance (errors to criterion), and exploratory open‑field activity to rule out motor confounds. Statistical plan: Two‑way ANOVA (treatment × microbiome integrity) with post‑hoc Tukey; significance set at p<0.05.

Falsifiability

If acarbose fails to elevate hippocampal butyrate, HDAC inhibition, or PSD‑95 modulation, or if behavioral flexibility improves without corresponding molecular changes, the hypothesis would be refuted. Conversely, demonstration that microbiota depletion or GPR109A blockade blocks both the biochemical and behavioral effects would support the proposed microbiome‑butyrate‑HDCA‑PSD‑95 cascade as a mechanistic link between acarbose‑induced metabolic flexibility and cognitive rejuvenation.